In accordance with the Electronic Communications Act, anyone who visits a website that uses cookies must be informed that the website contains cookies, and what these are used for. The visitor must also accept the use of cookies.

Cookies on our website

We use cookies to make the website function optimally for you as a visitor. There are three types of cookies that may be used on our website.

• Permanent cookie: Saved on your device for a set period of time. This cookie is used to improve your website experience.
• Session cookie: Stored temporarily in your device’s memory while you visit our website. Session cookies are removed when you close your browser.
• Statistics cookies. These are used by us to track statistics on the number of visitors to our website.

To avoid cookies

If you do not wish to accept cookies, you can change your browser settings to automatically deny cookies, or to inform you that a website contains cookies. Previously stored cookies can also be deleted via the browser. See your browser's help pages for more information.

If you choose not to accept cookies, some parts of our website may not function optimally for you.

Read more about cookies on The Swedish Post and Telecom Authority website.

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in phase II, while GS-073 is about to enter phase I.